DeepMed Research

ANRS, Emerging Infectious Diseases

🇫🇷France

Country: 🇫🇷France

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

Optimisation of Primary HIV1 Infection Treatment(ANRS 147 OPTIPRIM)

Phase 3

Completed

Conditions: HIV-1 Infections

Interventions: Drug: darunavir; ritonavir; emtricitabine/tenofovir
Drug: raltegravir; maraviroc; darunavir; ritonavir; tenofovir/emtricitabine

First Posted Date: 2009-12-16

Last Posted Date: 2014-02-05

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 90

Registration Number: NCT01033760

Locations: 🇫🇷
Hôpital Gustave Dron, Tourcoing, France

Raltegravir in Patients With End Stage Liver Disease and in Transplant Recipients

Phase 1

Completed

Conditions: HIV Infection
Liver Failure
Evidence of Liver Transplantation

Interventions: Drug: Raltegravir potassium

First Posted Date: 2009-12-01

Last Posted Date: 2013-07-18

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 14

Registration Number: NCT01022476

Locations: 🇫🇷
Service de Médecine Interne, Hôpital de Bicêtre, LE KREMLIN-BICETRE cedex, France

Study Comparing the Tolerability and Viral Reduction of the Combination of IFN a-2b XL + Ribavirin Versus Peg IFN a-2b + Ribavirin in Patients With Chronic Hepatitis C, Genotype 1 or 4

Phase 2

Conditions: Chronic Hepatitis C

Interventions: Drug: IFN alfa-2b XL 27 MUI + Ribavirin
Drug: IFN alfa-2b XL 36 MUI + Ribavirin
Drug: IFN peg alfa-2b 1.5 µg/kg + Ribavirin

First Posted Date: 2009-11-10

Last Posted Date: 2013-09-20

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 84

Registration Number: NCT01010646

Locations: 🇫🇷
Hôpital de la Croix Rousse, Lyon, France

Evaluation of Three Strategies of Second-line Antiretroviral Treatment in Africa (Dakar - Bobo-Dioulasso - Yaoundé)

Phase 3

Completed

Conditions: HIV
HIV Infections

Interventions: Drug: emtricitabine/tenofovir + lopinavir/ritonavir (WHO recommended second line)
Drug: abacavir + didanosine + lopinavir/ritonavir (WHO recommended second line)
Drug: emtricitabine/tenofovir + darunavir + ritonavir (Second line strategy under evaluation)

First Posted Date: 2009-06-25

Last Posted Date: 2017-02-27

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 454

Registration Number: NCT00928187

Locations: 🇧🇫
Day Hospital, CHU Sanou Souro, Bobo Dioulasso, Burkina Faso
🇨🇲
Day Hospital, Central Hospital, Yaounde, Cameroon
🇸🇳
Clinical Research and Training Center, Fann Hospital, Dakar, Senegal

Efficacy and Safety of Varenicline Among HIV-infected Patients

Phase 3

Completed

Conditions: HIV Infections
Tobacco Dependence

Interventions: Drug: Placebo
Drug: Varenicline

First Posted Date: 2009-06-11

Last Posted Date: 2014-07-29

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 248

Registration Number: NCT00918307

Locations: 🇫🇷
CHU de Bordeaux, Bordeaux, France

ANRS HC20 Effectiveness of an Optimized Anti HCV PegIFN-alpha2a + Ribavirin on Sustained Virological Response in Patients With HCV Genotype 1 and 4 Non Responders and Co-infected With HIV

Phase 2

Completed

Conditions: Hepatitis

Interventions: Drug: Peg-interféron alpha 2a + ribavirin

First Posted Date: 2009-05-13

Last Posted Date: 2013-03-29

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 58

Registration Number: NCT00901524

Locations: 🇫🇷
Hôpital Tenon Service des Maladies Infectieuses, Paris, France

Efficacy and Safety of 2 Raltegravir Doses in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis

Phase 2

Completed

Conditions: HIV Infections
Tuberculosis

Interventions: Drug: efavirenz
Drug: raltegravir

First Posted Date: 2009-01-14

Last Posted Date: 2013-07-17

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 155

Registration Number: NCT00822315

Locations: 🇧🇷
Ipec/Fiocruz, Rio de Janeiro, Brazil
🇧🇷
Hospitral Universitario Pr Edgar Santos, Salvador da Bahia, Brazil
🇫🇷
Hôpital Saint-Louis, Paris, France

and more 6 locations

Early and Intermittent Antiretroviral Therapy in Naive HIV Infected Adults

Phase 2

Completed

Conditions: HIV Infections

Interventions: Drug: Structured treatment interruption

First Posted Date: 2009-01-09

Last Posted Date: 2012-05-23

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 45

Registration Number: NCT00820118

Locations: 🇫🇷
Services maladies infectieuses et tropicales CHU, Dijon, France

Cohort Study of Volunteers That Have Participated to Preventive HIV-1 Vaccine Trials

Terminated

Conditions: HIV Infection
HIV Seronegativity

First Posted Date: 2008-11-13

Last Posted Date: 2017-06-01

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 488

Registration Number: NCT00789789

Locations: 🇫🇷
CIC Cochin Pasteur, hôpital Cochin, Paris, France

Trial Comparing Two Strategies of Vaccination Against Hepatitis B in HIV-infected Patients Non Responding to Primary Immunization (B-BOOST)

Phase 3

Completed

Conditions: Hepatitis B
HIV Infection

Interventions: Biological: GenHevac-B

First Posted Date: 2008-05-02

Last Posted Date: 2013-08-12

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 178

Registration Number: NCT00670839

Locations: 🇫🇷
Centre de Soins de l'Infection par le VIH NHC, Hôpitaux Universitaires Strasbourg, 1 place de l'hôpital, Strasbourg, France

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy